109 related articles for article (PubMed ID: 31259409)
1. Bioenergetic cellular index: a clinical biomarker to identify metabolic adaption in melanoma?
Armstrong J
Br J Dermatol; 2019 Jul; 181(1):15-16. PubMed ID: 31259409
[No Abstract] [Full Text] [Related]
2. Prognostic tissue markers in melanoma.
Moore DA; Pringle JH; Saldanha GS
Histopathology; 2012 Apr; 60(5):679-89. PubMed ID: 21880059
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic potential of the metabolic modulator phenformin in targeting the stem cell compartment in melanoma.
Petrachi T; Romagnani A; Albini A; Longo C; Argenziano G; Grisendi G; Dominici M; Ciarrocchi A; Dallaglio K
Oncotarget; 2017 Jan; 8(4):6914-6928. PubMed ID: 28036292
[TBL] [Abstract][Full Text] [Related]
4. TRIB2 as a biomarker for diagnosis and progression of melanoma.
Hill R; Kalathur RK; Colaço L; Brandão R; Ugurel S; Futschik M; Link W
Carcinogenesis; 2015 Apr; 36(4):469-77. PubMed ID: 25586991
[TBL] [Abstract][Full Text] [Related]
5. Molecular diagnosis of melanoma-have we arrived?
Bordelon JR; Grichnik JM
Dermatol Ther; 2015; 28(6):405. PubMed ID: 26031627
[No Abstract] [Full Text] [Related]
6. The immune system--a hidden treasure for biomarker discovery in cutaneous melanoma.
Neagu M
Adv Clin Chem; 2012; 58():89-140. PubMed ID: 22950344
[TBL] [Abstract][Full Text] [Related]
7. Identification of a Circulating MicroRNA Profile as a Biomarker of Metastatic Cutaneous Melanoma.
Armand-Labit V; Meyer N; Casanova A; Bonnabau H; Platzer V; Tournier E; Sansas B; Verdun S; Thouvenot B; Hilselberger B; Doncescu A; Lamant L; Lacroix-Triki M; Favre G; Pradines A
Acta Derm Venereol; 2016 Jan; 96(1):29-34. PubMed ID: 26039581
[TBL] [Abstract][Full Text] [Related]
8. Tumor biomarkers in melanoma.
Ugurel S; Utikal J; Becker JC
Cancer Control; 2009 Jul; 16(3):219-24. PubMed ID: 19556961
[TBL] [Abstract][Full Text] [Related]
9. Prognostic relationship of metabolic profile obtained of melanoma B16F10.
Fedele TA; Galdos-Riveros AC; Jose de Farias e Melo H; Magalhães A; Maria DA
Biomed Pharmacother; 2013 Mar; 67(2):146-56. PubMed ID: 23433855
[TBL] [Abstract][Full Text] [Related]
10. Molecular drivers of cellular metabolic reprogramming in melanoma.
Abildgaard C; Guldberg P
Trends Mol Med; 2015 Mar; 21(3):164-71. PubMed ID: 25618774
[TBL] [Abstract][Full Text] [Related]
11. Emerging Biomarkers in Cutaneous Melanoma.
Eisenstein A; Gonzalez EC; Raghunathan R; Xu X; Wu M; McLean EO; McGee J; Ryu B; Alani RM
Mol Diagn Ther; 2018 Apr; 22(2):203-218. PubMed ID: 29411301
[TBL] [Abstract][Full Text] [Related]
12. Prognostic and predictive biomarkers for the benefit of immunotherapy in patients with metastatic melanoma.
Chmielowski B
Br J Dermatol; 2016 Jan; 174(1):20. PubMed ID: 26790652
[No Abstract] [Full Text] [Related]
13. New insight into the role of metabolic reprogramming in melanoma cells harboring BRAF mutations.
Ferretta A; Maida I; Guida S; Azzariti A; Porcelli L; Tommasi S; Zanna P; Cocco T; Guida M; Guida G
Biochim Biophys Acta; 2016 Nov; 1863(11):2710-2718. PubMed ID: 27542908
[TBL] [Abstract][Full Text] [Related]
14. Malignant melanoma: advances in diagnosis, prognosis, and treatment.
Krathen M
Semin Cutan Med Surg; 2012 Mar; 31(1):45-9. PubMed ID: 22361289
[TBL] [Abstract][Full Text] [Related]
15. Clinical and biological determinants of melanoma progression: Should all be considered for clinical management?
Rowe CJ; Khosrotehrani K
Australas J Dermatol; 2016 Aug; 57(3):175-81. PubMed ID: 26010424
[TBL] [Abstract][Full Text] [Related]
16. EMMPRIN/CD147 is an independent prognostic biomarker in cutaneous melanoma.
Caudron A; Battistella M; Feugeas JP; Pages C; Basset-Seguin N; Mazouz Dorval S; Funck Brentano E; Sadoux A; Podgorniak MP; Menashi S; Janin A; Lebbé C; Mourah S
Exp Dermatol; 2016 Aug; 25(8):618-22. PubMed ID: 27060463
[TBL] [Abstract][Full Text] [Related]
17. Metastatic pathways in patients with cutaneous melanoma.
Adler NR; Haydon A; McLean CA; Kelly JW; Mar VJ
Pigment Cell Melanoma Res; 2017 Jan; 30(1):13-27. PubMed ID: 27900851
[TBL] [Abstract][Full Text] [Related]
18. Insulin-like growth factor-2 mRNA-binding protein 3 as a novel prognostic biomarker for acral lentiginous melanoma.
Seo JW; Ha SM; Song KH
Br J Dermatol; 2018 Apr; 178(4):e268-e270. PubMed ID: 29048737
[No Abstract] [Full Text] [Related]
19. Circulating melanoma cells as a potential biomarker to detect metastasis and evaluate prognosis.
Hida T; Yoneta A; Wakamatsu K; Yanagisawa K; Ishii-Osai Y; Kan Y; Kato J; Yamashita T
Australas J Dermatol; 2016 May; 57(2):145-9. PubMed ID: 26931184
[TBL] [Abstract][Full Text] [Related]
20. [Circulating prognosis markers in melanoma: proteomic profiling and clinical studies].
Solassol J; Guillot B; Maudelonde T
Ann Biol Clin (Paris); 2011; 69(2):151-7. PubMed ID: 21464007
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
